Search research articles
Contact Us
Filters
Showing results (21-30 of 33) with videos related to
Page
of 4
Sort By:
The Journal of Urology
|
June 16, 2007
Erectile function outcome reporting after clinically localized prostate cancer treatment
Arthur L Burnett, Gunnar Aus, Edith D Canby-Hagino, et al.
European Urology
|
July 13, 2024
Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial
Elizabeth R Plimack, Catherine Tangen, Melissa Plets, et al.
Lancet (London, England)
|
February 16, 2021
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial
Sumanta K Pal, Catherine Tangen, Ian M Thompson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 14, 2024
Reply to J.A. Garcia et al
Susan Halabi, Siyuan Guo, Akash Roy, et al.
JAMA Network Open
|
October 7, 2024
Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer
Amir Goldkorn, Catherine Tangen, Melissa Plets, et al.
The New England Journal of Medicine
|
November 26, 2024
Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer
Seth P Lerner, Catherine Tangen, Robert S Svatek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 10, 2024
Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma
Pedro Barata, Catherine Tangen, Melissa Plets, et al.
European Urology
|
May 29, 2024
Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial
Primo N Lara, Catherine Tangen, Elisabeth I Heath, et al.
European Urology Oncology
|
March 24, 2024
Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide
Mamta Parikh, Catherine Tangen, Maha H A Hussain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 27, 2021
Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216)
Amir Goldkorn, Catherine Tangen, Melissa Plets, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 33) with videos related to
Sort By:
Page
of 4
The Journal of Urology
|
June 16, 2007
Erectile function outcome reporting after clinically localized prostate cancer treatment
Arthur L Burnett, Gunnar Aus, Edith D Canby-Hagino, et al.
European Urology
|
July 13, 2024
Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial
Elizabeth R Plimack, Catherine Tangen, Melissa Plets, et al.
Lancet (London, England)
|
February 16, 2021
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial
Sumanta K Pal, Catherine Tangen, Ian M Thompson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 14, 2024
Reply to J.A. Garcia et al
Susan Halabi, Siyuan Guo, Akash Roy, et al.
JAMA Network Open
|
October 7, 2024
Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer
Amir Goldkorn, Catherine Tangen, Melissa Plets, et al.
The New England Journal of Medicine
|
November 26, 2024
Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer
Seth P Lerner, Catherine Tangen, Robert S Svatek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 10, 2024
Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma
Pedro Barata, Catherine Tangen, Melissa Plets, et al.
European Urology
|
May 29, 2024
Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial
Primo N Lara, Catherine Tangen, Elisabeth I Heath, et al.
European Urology Oncology
|
March 24, 2024
Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide
Mamta Parikh, Catherine Tangen, Maha H A Hussain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 27, 2021
Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216)
Amir Goldkorn, Catherine Tangen, Melissa Plets, et al.
Page
of 4